📰 Mapi Research News
Mapi Research News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Mapi Research. Real-time updates on events, politics, business and more.
July 31, 2023
Operator: Hello, and welcome to the ICON plc Q2 2023 Results Conference Call. At this time, all participants are in a listen only mode.
June 26, 2023
Latest features support greater patient centricity and speed in study start-up
March 29, 2023
SAN ANTONIO — A high proportion of patients with eosinophilic esophagitis also had simultaneous atopic or allergic comorbid conditions, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.Eosinophilic esophagitis (EoE) is a chronic, progressive type II inflammatory disease, Marc E. Rothenberg, MD, PhD, director of the Cincinnati Center for
March 28, 2023
/PRNewswire/ -- The global eCOA solution market size is estimated to grow by USD 1,285.69 million from 2022 to 2027, according to Technavio. The market is...
December 8, 2022
BIRMINGHAM, England, Dec. 8, 2022 /PRNewswire/ -- A validated Symptom Burden Questionnaire that will help medical researchers unravel the complexities of Long COVID and develop or test new treatments
September 21, 2022
Toronto, ON (PRWEB) September 21, 2022 -- In today’s patient-driven and competitive drug development landscape, healthcare organizations and related clinical
May 23, 2022
Background: The human immunodeficiency virus (HIV) infection and its treatment impact the child’s life as well as that of their caregivers. As therapeutic advances are made in the field, improved survival has shifted the focus from morbidity and mortality to quality of life. This study aims to compare the health-related quality of life (HRQoL) of children living with HIV in comparison with an HIV-negative control group and determine its relationship with socio-demographic, clinical, and nutri...
March 3, 2022
In a phase 3 trial of adults and adolescents with hard-to-treat eosinophilic esophagitis, 6 months of weekly dupilumab sent 59% of participants into disease remission.